Nuvalent, INC Form 4 insider transactions

Director Matthew Shair of Nuvalent, Inc. sold a portion of his Class A Common Stock holdings under a pre-arranged 10b5-1 trading plan.

Nuvalent's CEO, James Richard Porter, exercised stock options to acquire 22,000 shares of Class A Common Stock at $0.65 per share.

Nuvalent's Chief Financial Officer, Alexandra Balcom, exercised stock options, acquiring 13,700 shares of Class A Common Stock at prices of $1.08 and $6.89 per share.

Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc., reports exercising stock options to acquire Class A Common Stock at prices of $0.65 and $0.87.

Nuvalent's CEO, James Richard Porter, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Director Andrew Hack of Nuvalent, Inc. sold 1,250,000 shares of Class A Common Stock at $88 per share on December 11, 2024.

Director Grant C. Bogle of Nuvalent, Inc. acquired 3,200 shares of Class A Common Stock and options for 4,851 shares on December 5, 2024.

Nuvalent's Chief Financial Officer, Alexandra Balcom, engaged in multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Director Matthew Shair of Nuvalent, Inc. sold a portion of his Class A Common Stock holdings under a pre-arranged 10b5-1 trading plan.

Nuvalent's CEO, James Porter, engaged in multiple stock transactions, including both the acquisition and sale of shares, under a pre-arranged 10b5-1 trading plan.

Darlene Noci, Chief Development Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Alexandra Balcom, CFO of Nuvalent, Inc., executed multiple sales of Class A Common Stock on October 31, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Matthew Shair of Nuvalent, Inc. executed sales of Class A Common Stock on October 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

James E. Flynn, along with several Deerfield entities, reported the disposal of 2,000,000 shares of Nuvalent, Inc. (NUVL) Class A Common Stock at a price of $97.75 per share.

Nuvalent's CEO, James Richard Porter, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Darlene Noci, Chief Development Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Alexandra Balcom, CFO of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock on September 30, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Matthew Shair, a director at Nuvalent, Inc., executed multiple sales of Class A Common Stock on September 23, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc., sold shares of Class A Common Stock on September 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Deborah Ann Miller, Chief Legal Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock on September 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Deborah Ann Miller, Chief Legal Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Darlene Noci, Chief Development Officer of Nuvalent, Inc., executed sales of Class A Common Stock on September 3, 2024, under a pre-arranged 10b5-1 trading plan.

Nuvalent's CFO, Alexandra Balcom, exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Director Matthew Shair sold shares of Nuvalent, Inc. (NUVL) on August 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc., sold 10,500 shares of Class A Common Stock at an average price of $85.08 on August 23, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Deborah Ann Miller, Chief Legal Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Director Emily Conley exercised stock options and sold shares of Nuvalent, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Deborah Ann Miller, Chief Legal Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan on August 8, 2024.

Darlene Noci, Chief Development Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Alexandra Balcom, CFO of Nuvalent, Inc., reports the sale of Class A Common Stock on July 31, 2024, under a pre-arranged Rule 10b5-1 trading plan.